TEVA : Analysis & Opinions

  1. Akorn Scores A Rare Win-Win Acquisition

    August 27, 2013
    Akorn builds value by buying Hi-Tech
  2. Novo Nordisk Getting Its Trial By Fire

    August 8, 2013
    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  3. MediciNova Presents MN-166 Data - Analyst Blog

    June 19, 2013
    MediciNova announced the presentation of preliminary data from a phase Ib study of MN-166 for the treatment of methamphetamine ...
  4. Teva to Acquire MicroDose Therapeutx - Analyst Blog

    June 18, 2013
    This deal is in line with Teva's strategy of strengthening its position in the respiratory therapeutic area.
  5. $2.15B Settlement for Pfizer's Protonix - Analyst Blog

    June 13, 2013
    While Teva will make a payment of $1.6 billion, Sun Pharma will pay the remaining $550 million.
  6. SGEN Starts Adcetris Phase I/II Study - Analyst Blog

    June 11, 2013
    Seattle Genetics commenced a phase I/II study to evaluate Adcetris in combination with Teva Pharma's Treanda (bendamustine) ...
  7. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  8. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  9. Natural Gas: A Big Win For Israel And Its Producers

    April 2, 2013
    While it’s a tech powerhouse, the natural gas game is quickly changing Israel’s economy for the good. The recent prolific ...
  10. OncoGenex' Candidate Progresses - Analyst Blog

    February 14, 2013
    OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it is looking to move its oncology candidate, OGX-427, into ...
  11. Teva Misses, Hikes Dividend - Analyst Blog

    February 8, 2013
    Teva Pharmaceutical Industries (TEVA) reported fourth quarter earnings of $1.32 per American Depositary Share (ADS), a penny ...
  12. Teva Ends CureTech Collaboration - Analyst Blog

    February 4, 2013
    Teva Pharmaceutical Industries Ltd. (TEVA) recently terminated its collaboration with CureTech Ltd. for the development of ...
  13. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  14. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  15. Disappointing Data from Teva - Analyst Blog

    January 24, 2013
    Teva Pharmaceutical Industries Ltd. (TEVA) recently announced disappointing top-line results from a study evaluating Nuvigil ...
  16. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  17. Bayer Takes Over Teva Unit - Analyst Blog

    January 7, 2013
    The HealthCare unit of Bayer AG (BAYRY) recently received the necessary regulatory approval from the Federal Trade Commission ...
  18. An End to Drug Patent Woes? - Analyst Blog

    December 14, 2012
    The US Supreme Court will soon hear a case which will determine whether "pay-for-delay" agreements between drug manufacturers ...
  19. Eli Lilly and Other Healthcare Stocks Making Big Moves on December ...

    December 12, 2012
    The Nasdaq remains relatively unchanged, the S&P 500 has moved up 0.2% and the Dow is up 0.2% after the morning's trading. ...
  20. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  21. Teva's Guidance Lags Expectations - Analyst Blog

    December 4, 2012
    Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2013. The company expects to earn $4.85 and $5.15 ...
  22. Early Research Calls

    November 28, 2012
    New York, May 10th ( - Research Analyst's early calls ahead of the bell. Prudential (NYSE:PRU) was upgraded ...
  23. Bayer Scraps Schiff Nutrition Deal - Analyst Blog

    November 27, 2012
    Bayer (BAYRY) recently announced that it will not go ahead with its proposed acquisition of nutritional supplement company ...
  24. Forest Inks Alzheimer's Drug Deal - Analyst Blog

    November 15, 2012
    Forest Laboratories, Inc. (FRX) is taking steps to extend the lifecycle of its Alzheimer's disease product, Namenda (memantine ...
  25. Jazz Pharma 3Q Earnings In Line - Analyst Blog

    November 9, 2012
    Jazz Pharmaceuticals plc (JAZZ) reported third quarter 2012 earnings (including share-based compensation charges but excluding ...
  26. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  27. Generic Launches at Watson Pharma - Analyst Blog

    October 23, 2012
    Watson Pharmaceuticals, Inc. (WPI) recently announced that it has gained US Food and Drug Administration (FDA) approval for ...
  28. Jazz Divests Women's Health Suite - Analyst Blog

    October 22, 2012
    Jazz Pharmaceuticals plc (JAZZ) recently completed the sale of its women's health business to Meda Pharmaceuticals Inc., ...
  29. FDA Extends Review of Impax' IPX066 - Analyst Blog

    October 16, 2012
    The US Food and Drug Administration (FDA) recently extended the Prescription Drug User Fee Act (PDUFA) date for Impax Laboratories, ...
  30. FDA Approval for Perrigo Product - Analyst Blog

    October 11, 2012
    The US Food and Drug Administration (FDA) recently approved Perrigo Company's (PRGO) Abbreviated New Drug Applications (ANDAs) ...
  31. Mylan in Neutral Lane - Analyst Blog

    October 10, 2012
    We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $26.00. The stock carries a Zacks ...
  32. EC Nod for Watson's Actavis Deal - Analyst Blog

    October 9, 2012
    Watson Pharmaceuticals, Inc. (WPI) recently received the green signal from the European Commission (EC) for its proposed ...
  33. New Ratings

    October 9, 2012
    New York, May 23rd ( - These are the research analyst new ratings before the market open. Travelers ...
  34. Perrigo Eyes Pet Care Market - Analyst Blog

    September 17, 2012
    In a bid to diversify its business into the pet care space, Perrigo Company (PRGO) inked a deal to buy substantially the ...
  35. Shire Settles Patent Dispute - Analyst Blog

    September 12, 2012
    Shire LLC, a subsidiary of Shire plc (SHPG) recently announced that it has entered into a settlement agreement with Anchen ...
  36. Teva's Quartette Filing Accepted - Analyst Blog

    August 20, 2012
    Teva Pharmaceutical Industries Ltd.'s (TEVA) subsidiary, Teva Women's Health, Inc., recently announced the acceptance of ...
  37. Generics Launches at Mylan - Analyst Blog

    August 14, 2012
    Mylan Inc. (MYL) recently announced that it has launched its generic version of Noven Therapeutics' Lithobid (lithium carbonate) ...
  38. Par Pharma Beats Estimates - Analyst Blog

    August 6, 2012
    Par Pharmaceutical Companies Inc. (PRX) posted second quarter 2012 adjusted earnings of $1.62 per share, well above the Zacks ...
  39. Hi-Tech Pharmacal An Under Followed Name Worth Following

    July 12, 2012
    Hi-Tech Pharmacal gets little attention, but maybe it should.
  40. MDCO's Cangrelor Enrollment by 4Q - Analyst Blog

    July 3, 2012
    The Medicines Company (MDCO) recently announced that patient enrollment for its pivotal phase III CHAMPION PHOENIX trial ...
  41. NYSE's Biggest Movers for June 25, 2012

    June 25, 2012
    The market is off to a rough start. After this morning's trading, the Nasdaq has decreased 2%, the S&P 500 is down 1.7% and ...
  42. Biggest Healthcare Sector Movers for June 25, 2012

    June 25, 2012
    The Nasdaq has declined 2%, the S&P 500 has fallen 1.7% and the Dow has slipped 1.3% on a bad morning for the market. The ...
  43. Forest Labs Slashes Outlook - Analyst Blog

    June 12, 2012
    Forest Laboratories, Inc. (FRX) recently slashed its outlook for fiscal 2013 mainly due to lower expectations from Lexapro. ...
  44. Aceto Looking At A Tough Future

    May 15, 2012
    Aceto is making sound moves, but the results need to be better.
  45. Countdown Has Begun for 7 Rising Biotechs

    March 13, 2012
    If you're looking for cutting-edge companies that have a chance to triple or quadruple in the coming months and years, don't ...
  46. Growth Stocks Not Necessarily Risky

    March 8, 2012
    By looking at growth and value investment as two sides of the same coin, growth stocks like Disney aren't neccessarily risky ...
  47. Diversified Investment Appeal From Novartis

    January 27, 2012
    The healthcare giant reported impressive results in 2011 and offers a reasonable valuation and solid dividends.
  48. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  49. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  50. Medicis May Not Stay Independent

    November 10, 2011
    Medicis is well-run, but arguably too risky to stay independent.
  51. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  52. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  53. MHS-ESRX Merger Will Force Interesting Choice In Washington

    July 28, 2011
    Express Scripts is taking a bold move to become a titan of its industry.
  54. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  55. Transcept Pharmaceuticals Bulls Get Rude Awakening

    July 15, 2011
    Transcept gets a major setback, but it may not be doomed.
  56. The Best Of Both Worlds With The TICK

    July 5, 2011
    The TICK blends the best of both the developed and developing nations.
  57. With Mylan, Maybe Smaller Is Better

    May 6, 2011
    Mylan is not the biggest or the best, but the valuation here makes it worth a look.
  58. A Chance To Add Healthcare

    May 6, 2011
    The healthcare sector is still a bargain - and that alone should keep it in investors' minds.
  59. J&J Beats Analyst Expections, But Not Its Rivals

    April 25, 2011
    Tangible signs of sustained sales growth and consistent profit expansion are still absent at J&J.
  60. Investing In Tech Through Emerging Markets

    March 23, 2011
    Moving beyond low-cost production foundries, many emerging markets such as israel, South Korea and Taiwan are experiencing ...
  61. Medicis - Generic Reprieve And Shareholder Relief

    March 2, 2011
    Medicis gets a big boost from patent settlements.
  62. Pfizer Pleases Investors

    February 3, 2011
    The market is praising Pfizer's decision to cut back on R&D and focus funds on repurchasing its attractively-priced stock.
  63. Risk With Little Reward At Johnson & Johnson

    January 27, 2011
    A number of Johnson & Johnson rivals trade at equally appealing valuations and have their acts together in terms of product ...
  64. Playing Tech Through Emerging Markets

    January 5, 2011
    Moving beyond low-cost production foundries, many emerging markets such as israel, South Korea and Taiwan are experiencing ...
  65. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact does it ...
  66. AmerisourceBergen Riding Favorable Industry Tailwinds

    November 4, 2010
    At the current valuation, the stock of AmerisourceBergen is a worthy investment candidate for investor portfolios.
  67. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  68. Biosimilars - The Next Generic Honeypot

    August 10, 2010
    With the first biosimilar approval in over a decade, a major new market for generics could be on the horizon
  69. Investing In Israel

    July 29, 2010
    Israel offers solid fundamentals with the high-growth potential of a tech economy.
  70. Lilly's Top-Line Predicament

    April 21, 2010
    Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament.
  71. Three Middle Eastern Jewels

    April 9, 2010
    The Middle East offers opportunity for long-term investors in Egypt, Israel and Turkey.
  72. Weak Dollar And Low Valuation To Boost J&J

    October 15, 2009
    A couple of key investment merits should eventually allow J&J’s share price to increase markedly.
  73. J&J Looks To Get Back On Track

    July 15, 2009
    Investors are waiting for J&J to return to its heyday of double-digit growth.
  74. Emerging Market Focus

    April 15, 2009
    President Obama reminds investors of the importance of emerging markets.
  75. Make Some $$$s From Your Lack Of ZZZs

    March 9, 2009
    If you're losing sleep over the down economy, these pharmaceutical picks might help you sleep a little easier.
  76. Sleep Easy With Abbott Labs

    October 3, 2008
    Security and stability reign at Abbott Labs. The drug maker has avoided major recalls and has rock solid patent protection.
  77. Buyout Or Sellout Time At Biovail

    March 4, 2008
    Troubled drugmaker Biovail could be in play as Eugene Melnyk said he'll either sell his 11% stake or take the company private.
  78. Barr Encountering Acquisition Realities (BRL)

    April 19, 2007
    A look at the possible growing pains for the generic-drug manufacturing giant after it acquired Crotian drug producer PLIVA. ...
  79. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  80. Pfizer's Down, But Not Out (PFE)

    January 24, 2007
    While Pfizer's current issues are cause for concern, the company's long-term plans make it worth a second look.
  81. Can Genentech Go Higher?

    April 13, 2006
    A look at the recent quarter of one of the leading biotech companies.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center